Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.
Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.
复制标题
DOI：
10.1155/2013/602417
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Carr A
中科院分区：
文献类型：
--
作者：
Blanco R;Quintana Y;Blanco D;Cedeño M;Rengifo CE;Frómeta M;Ríos M;Rengifo E;Carr A
N-羟乙酰神经氨酸在人体中的表达形成神经节苷脂和/或其他糖缀合物（Hanganutziu-Deicher抗原）的结构，被认为是肿瘤相关抗原。具体而言，最近发表了一些关于14 F7 Mab（一种针对N-羟乙酰GM 3神经节苷脂的高度特异性Mab）在人类肿瘤中的反应性的报告。然而，上皮来源的肿瘤大多已被评估。本论文的目的是评估14 F7单克隆抗体在不同的人类肿瘤的神经外胚层，中胚层和上皮起源使用免疫过氧化物酶染色方法的免疫组化识别。胎儿、正常和反应性星形细胞增多症的脑样本也包括在研究中。一般来说，非肿瘤组织，以及，低级别的脑肿瘤显示没有或有限的免疫反应与14 F7单克隆抗体。然而，高级别星形细胞瘤（III-IV）和神经母细胞瘤，以及肉瘤和甲状腺癌大多与14 F7反应。在髓母细胞瘤和室管膜母细胞瘤中未发现反应。我们的数据表明，N-羟乙酰GM 3神经节苷脂的表达可能与恶性细胞的侵袭行为，而不依赖于肿瘤的起源。我们的数据也可以支持N-羟乙酰GM 3作为表达该分子的恶性肿瘤的主动和被动免疫疗法的靶点的可能用途。
The expression of N-glycolylneuraminic acid forming the structure of gangliosides and/or other glycoconjugates (Hanganutziu-Deicher antigen) in human has been considered as a tumor-associated antigen. Specifically, some reports of 14F7 Mab (a highly specific Mab raised against N-glycolyl GM3 ganglioside) reactivity in human tumors have been recently published. Nevertheless, tumors of epithelial origin have been mostly evaluated. The goal of the present paper was to evaluate the immunohistochemical recognition of 14F7 Mab in different human tumors of neuroectodermal, mesodermal, and epithelial origins using an immunoperoxidase staining method. Samples of fetal, normal, and reactive astrocytosis of the brain were also included in the study. In general, nontumoral tissues, as well as, low-grade brain tumors showed no or a limited immunoreaction with 14F7 Mab. Nevertheless, high-grade astrocytomas (III-IV) and neuroblastomas, as well as, sarcomas and thyroid carcinomas were mostly reactive with 14F7. No reaction was evidenced in medulloblastomas and ependymoblastomas. Our data suggest that the expression of N-glycolyl GM3 ganglioside could be related to the aggressive behavior of malignant cells, without depending on the tumor origin. Our data could also support the possible use of N-glycolyl GM3 as a target for both active and passive immunotherapies of malignancies expressing this molecule.